Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.

IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL
Shahrzad Ahangarzadeh, Elmira Mohammadi, Hajar Yaghoobi, Kiana Shahzamani, Armina Alagheband Bahrami, Roghaye Arezumand, Leila Beikmohammadi, Abbas Alibakhshi
{"title":"Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.","authors":"Shahrzad Ahangarzadeh, Elmira Mohammadi, Hajar Yaghoobi, Kiana Shahzamani, Armina Alagheband Bahrami, Roghaye Arezumand, Leila Beikmohammadi, Abbas Alibakhshi","doi":"10.2174/0118715206369319250402150638","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy is becoming an alternative method for gastrointestinal cancers, such as colorectal, gastric, and liver cancers. This field of research focuses on utilizing the immune system to recognize and eliminate cancer cells. One important method is immune checkpoint inhibitors, which enable T cells to recognize and attack tumor cells by releasing the immune system's brakes. Chimeric antigen receptor (CAR) T-cell therapy is another approach that modifies a patient's T cells to express receptors specific to tumor-associated antigens. Some cancer vaccines have demonstrated positive results in clinical trials, particularly colorectal and gastric cancers. Despite progress, challenges exist in immunotherapy for gastrointestinal cancers, such as treatment resistance, limited biomarkers for patient selection, and identifying new targets. In this review, different immunotherapy methods for all types of gastrointestinal cancers will be studied, and the limitations and benefits of each will be discussed in detail. By delving into the various immunotherapy methods, their limitations, and benefits, this review offers valuable insights that could potentially shape the future of gastrointestinal cancer treatment. It not only sheds light on the promising advancements in immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines but also highlights the existing challenges that demand further research and innovation.</p>","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715206369319250402150638","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Immunotherapy is becoming an alternative method for gastrointestinal cancers, such as colorectal, gastric, and liver cancers. This field of research focuses on utilizing the immune system to recognize and eliminate cancer cells. One important method is immune checkpoint inhibitors, which enable T cells to recognize and attack tumor cells by releasing the immune system's brakes. Chimeric antigen receptor (CAR) T-cell therapy is another approach that modifies a patient's T cells to express receptors specific to tumor-associated antigens. Some cancer vaccines have demonstrated positive results in clinical trials, particularly colorectal and gastric cancers. Despite progress, challenges exist in immunotherapy for gastrointestinal cancers, such as treatment resistance, limited biomarkers for patient selection, and identifying new targets. In this review, different immunotherapy methods for all types of gastrointestinal cancers will be studied, and the limitations and benefits of each will be discussed in detail. By delving into the various immunotherapy methods, their limitations, and benefits, this review offers valuable insights that could potentially shape the future of gastrointestinal cancer treatment. It not only sheds light on the promising advancements in immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines but also highlights the existing challenges that demand further research and innovation.

癌症免疫治疗的先进技术:聚焦胃肠道癌症。
免疫疗法正在成为结肠直肠癌、胃癌、肝癌等胃肠道肿瘤的替代治疗方法。这一领域的研究重点是利用免疫系统来识别和消除癌细胞。一种重要的方法是免疫检查点抑制剂,它通过释放免疫系统的刹车,使T细胞能够识别和攻击肿瘤细胞。嵌合抗原受体(CAR) T细胞疗法是另一种改变患者T细胞以表达肿瘤相关抗原特异性受体的方法。一些癌症疫苗在临床试验中显示出积极的效果,特别是结肠直肠癌和胃癌。尽管取得了进展,但胃肠道癌症的免疫治疗仍存在挑战,如治疗耐药性,患者选择的生物标志物有限,以及确定新的靶点。在这篇综述中,不同的免疫治疗方法对所有类型的胃肠道癌症将进行研究,并详细讨论每种方法的局限性和益处。通过深入研究各种免疫治疗方法及其局限性和益处,本综述提供了有价值的见解,可能会影响胃肠道癌症治疗的未来。它不仅揭示了免疫检查点抑制剂、CAR - t细胞疗法和癌症疫苗的有希望的进展,而且还强调了需要进一步研究和创新的现有挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anti-cancer agents in medicinal chemistry
Anti-cancer agents in medicinal chemistry ONCOLOGY-CHEMISTRY, MEDICINAL
CiteScore
5.10
自引率
3.60%
发文量
323
审稿时长
4-8 weeks
期刊介绍: Formerly: Current Medicinal Chemistry - Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents. Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication. Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信